Stock Markets July 2, 2026 05:04 PM

Seer shares surge after CEO proposes $2.45-per-share buyout with contingent payouts

Board to form independent Special Committee to assess unsolicited, non-binding offer from Chair and CEO

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
SEER

Seer Inc. shares rose sharply in after-hours trading following an unsolicited, non-binding proposal from the company’s Chair and CEO to acquire all outstanding Class A common stock for $2.45 per share in cash plus two contingent value rights. The Board will appoint a Special Committee of independent directors to evaluate the offer, consider alternatives and engage independent advisors.

Seer shares surge after CEO proposes $2.45-per-share buyout with contingent payouts
SEER
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Seer's Chair and CEO Omid Farokhzad submitted an unsolicited, non-binding proposal to buy all Class A common stock at $2.45 per share in cash plus two contingent value rights.
  • The Board will appoint a Special Committee of independent directors to evaluate the proposal and consider other strategic alternatives, supported by independent financial and legal advisers.
  • Perella Weinberg Partners is acting as financial advisor to Seer and Wilson Sonsini Goodrich & Rosati is serving as legal counsel; the full proposal letter will be included in a Form 8-K and no stockholder action is required now.

Shares of Seer Inc (NASDAQ:SEER) climbed roughly 30% in after-hours trading Thursday after the company's Chair and Chief Executive Officer submitted an unsolicited proposal to purchase the company's Class A shares.

Omid Farokhzad, who holds the combined roles of Chair and CEO, put forward a non-binding offer to acquire all outstanding shares of Seer's Class A common stock at a price of $2.45 per share in cash. The proposed consideration also includes two separate contingent value rights.

In response, Seer's Board of Directors said it will form a Special Committee composed exclusively of independent directors to review the proposal. The committee's mandate will include assessing the CEO's submission, exploring other strategic alternatives available to the company and deciding the course of action it deems to be in the best interests of Seer and its stockholders.

The Special Committee will be supported by independent financial and legal advisers during its review. Seer has named Perella Weinberg Partners as its financial advisor, while Wilson Sonsini Goodrich & Rosati will serve as legal counsel.

The full text of the letter from Mr. Farokhzad that sets out the acquisition proposal will be filed by Seer as part of a Form 8-K. The company also indicated that no action by stockholders is required at this time.

Seer, based in Redwood City, California, develops proteomics technology marketed under its Proteograph Product Suite. The suite combines engineered nanoparticles, automation instrumentation, consumables and analytical software. Seer specifies that its products are intended for research use only and are not designed for diagnostic purposes.


Summary of current procedural steps:

  • The Board will establish a Special Committee of independent directors to evaluate the unsolicited offer.
  • The Special Committee will retain independent financial and legal advisors to assist the review; Perella Weinberg Partners and Wilson Sonsini Goodrich & Rosati are named advisers.
  • The letter from the CEO detailing the proposal will be included in a Form 8-K filing; no stockholder action is required at this time.

This development follows an after-hours market move and initiates a formal governance process to assess the proposed transaction and any alternatives the Board may identify.

Risks

  • The CEO's proposal is non-binding, so the offer may not result in a completed transaction and could be revised or withdrawn, impacting investor expectations - affects equity markets and M&A activity in the biotech sector.
  • The Special Committee may determine alternatives that differ from the CEO's proposal or reject the offer, creating uncertainty for shareholders until a definitive outcome is reached - impacts corporate governance and shareholder decision-making in the company.
  • Contingent value rights introduce future payout uncertainty tied to conditions not detailed in the filing, which may affect the ultimate value delivered to shareholders - relevant to valuation and investor risk assessment in proteomics and life sciences equities.

More from Stock Markets

QTS Pulls the Plug on Digital Gateway Data Center in Virginia Jul 2, 2026 Texas man charged with manslaughter after Tesla crashes into Katy home, killing 76-year-old woman Jul 2, 2026 Kioxia to Begin Mass Production of 10th-Gen NAND as AI Demand Drives Rapid Rebound Jul 2, 2026 Londian Wason Energy Tech Files for NYSE IPO to Fund Battery Foil Expansion Jul 2, 2026 Crusoe Eyes $3 Billion Raise as AI Demand Lifts Its Valuation Jul 2, 2026